141 related articles for article (PubMed ID: 38513335)
1. Comparative effectiveness and mortality of colistin monotherapy versus colistin-fosfomycin combination therapy for the treatment of carbapenem-resistant Enterobacteriaceae (CRE) infections: A propensity score analysis.
Katip W; Rayanakorn A; Oberdorfer P; Taruangsri P; Nampuan T; Okonogi S
J Infect Public Health; 2024 May; 17(5):727-734. PubMed ID: 38513335
[TBL] [Abstract][Full Text] [Related]
2. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.
van Duin D; Lok JJ; Earley M; Cober E; Richter SS; Perez F; Salata RA; Kalayjian RC; Watkins RR; Doi Y; Kaye KS; Fowler VG; Paterson DL; Bonomo RA; Evans S;
Clin Infect Dis; 2018 Jan; 66(2):163-171. PubMed ID: 29020404
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility profile, resistance mechanisms & efficacy ratios of fosfomycin, nitrofurantoin & colistin for carbapenem-resistant
Amladi AU; Abirami B; Devi SM; Sudarsanam TD; Kandasamy S; Kekre N; Veeraraghavan B; Sahni RD
Indian J Med Res; 2019 Feb; 149(2):185-191. PubMed ID: 31219082
[TBL] [Abstract][Full Text] [Related]
4. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.
Machuca I; Gutiérrez-Gutiérrez B; Gracia-Ahufinger I; Rivera Espinar F; Cano Á; Guzmán-Puche J; Pérez-Nadales E; Natera C; Rodríguez M; León R; Castón JJ; Rodríguez-López F; Rodríguez-Baño J; Torre-Cisneros J
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559247
[TBL] [Abstract][Full Text] [Related]
5. The role of therapy with aminoglycoside in the outcomes of kidney transplant recipients infected with polymyxin- and carbapenem-resistant Enterobacteriaceae.
Freire MP; de Oliveira Garcia D; Cury AP; Francisco GR; Dos Santos NF; Spadão F; Bueno MFC; Camargo CH; de Paula FJ; Rossi F; Nahas WC; David-Neto E; Pierrotti LC
Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):755-765. PubMed ID: 30680569
[TBL] [Abstract][Full Text] [Related]
6. High rate of colistin and fosfomycin resistance among carbapenemase-producing Enterobacteriaceae in Turkey.
Süzük Yıldız S; Kaşkatepe B; Şimşek H; Sarıgüzel FM
Acta Microbiol Immunol Hung; 2019 Mar; 66(1):103-112. PubMed ID: 30403361
[TBL] [Abstract][Full Text] [Related]
7. Carbapenem and colistin resistance in children with Enterobacteriaceae infections.
Haytoğlu Z; Gündeşlioğlu ÖÖ; Yıldızdaş D; Kocabaş E; Alabaz D; Horoz ÖÖ
Turk J Pediatr; 2020; 62(5):778-786. PubMed ID: 33108080
[TBL] [Abstract][Full Text] [Related]
8. Short versus long course of colistin treatment for carbapenem-resistant A. baumannii in critically ill patients: A propensity score matching study.
Katip W; Rayanakorn A; Oberdorfer P; Taruangsri P; Nampuan T
J Infect Public Health; 2023 Aug; 16(8):1249-1255. PubMed ID: 37295057
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia.
Hakeam HA; Alsahli H; Albabtain L; Alassaf S; Al Duhailib Z; Althawadi S
Int J Infect Dis; 2021 Aug; 109():1-7. PubMed ID: 34091006
[TBL] [Abstract][Full Text] [Related]
10. Management of carbapenem-resistant Enterobacteriaceae infections.
Durante-Mangoni E; Andini R; Zampino R
Clin Microbiol Infect; 2019 Aug; 25(8):943-950. PubMed ID: 31004767
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic options for carbapenem-resistant Enterobacteriaceae infections.
Trecarichi EM; Tumbarello M
Virulence; 2017 May; 8(4):470-484. PubMed ID: 28276996
[TBL] [Abstract][Full Text] [Related]
12. A prospective study of treatment of carbapenem-resistant Enterobacteriaceae infections and risk factors associated with outcome.
de Maio Carrilho CM; de Oliveira LM; Gaudereto J; Perozin JS; Urbano MR; Camargo CH; Grion CM; Levin AS; Costa SF
BMC Infect Dis; 2016 Nov; 16(1):629. PubMed ID: 27809803
[TBL] [Abstract][Full Text] [Related]
13. Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections.
Ku K; Pogue JM; Moshos J; Bheemreddy S; Wang Y; Bhargava A; Campbell M; Khandker N; Lephart PR; Chopra T; Hayakawa K; Martin ET; Abreu-Lanfranco O; Dhar S; Kaye KS; Marchaim D
Am J Infect Control; 2012 Dec; 40(10):983-7. PubMed ID: 22440526
[TBL] [Abstract][Full Text] [Related]
14. Options for treating carbapenem-resistant Enterobacteriaceae.
Rafailidis PI; Falagas ME
Curr Opin Infect Dis; 2014 Dec; 27(6):479-83. PubMed ID: 25259809
[TBL] [Abstract][Full Text] [Related]
15. Retrospective Observational Study from a Chinese Network of the Impact of Combination Therapy versus Monotherapy on Mortality from Carbapenem-Resistant
Wang X; Wang Q; Cao B; Sun S; Zhang Y; Gu B; Li B; Liao K; Zhao F; Jin L; Jin C; Yang C; Pei F; Zhang Z; Wang H
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30348660
[TBL] [Abstract][Full Text] [Related]
16. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant
Ackley R; Roshdy D; Meredith J; Minor S; Anderson WE; Capraro GA; Polk C
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094128
[TBL] [Abstract][Full Text] [Related]
17. A retrospective observational cohort study of the clinical epidemiology of bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae in an OXA-48 endemic setting.
Aslan AT; Kırbaş E; Sancak B; Tanrıverdi ES; Otlu B; Gürsoy NC; Yılmaz YA; Tozluyurt A; Liste Ü; Bıçakcıgil A; Hazırolan G; Dağ O; Güven GS; Akova M;
Int J Antimicrob Agents; 2022 Apr; 59(4):106554. PubMed ID: 35176476
[TBL] [Abstract][Full Text] [Related]
18. Carbapenem-Containing Combination Antibiotic Therapy against Carbapenem-Resistant Uropathogenic
Loose M; Link I; Naber KG; Wagenlehner FME
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31636073
[TBL] [Abstract][Full Text] [Related]
19. A Matched Case-Case-Control Study of the Impact of Clinical Outcomes and Risk Factors of Patients with IMP-Type Carbapenemase-Producing Carbapenem-Resistant
Saito S; Hayakawa K; Tsuzuki S; Ishikane M; Nagashima M; Mezaki K; Sugiki Y; Tajima T; Matsunaga N; Ide S; Kinoshita N; Kusama Y; Fujitomo Y; Nakamoto T; Toda Y; Kaku M; Kodama EN; Ohmagari N
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33257451
[TBL] [Abstract][Full Text] [Related]
20. Risk factors and outcomes associated with the isolation of polymyxin B and carbapenem-resistant Enterobacteriaceae spp.: A case-control study.
Teo JQ; Chang CW; Leck H; Tang CY; Lee SJ; Cai Y; Ong RT; Koh TH; Tan TT; Kwa AL
Int J Antimicrob Agents; 2019 May; 53(5):657-662. PubMed ID: 30880229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
